Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Ibrutinib plus Rituximab in Japanese Patients with Waldenstrom's Macroglobulinemia
jRCT2080224857Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and rituximab in Waldenström macroglobulinemia (WM), sponsored by Janssen Pharmaceutical. Started Sep 2019; status: completed.
02
Drugs
ibrutinibrituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on jRCT2080224857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224857.